TCGA-AC-A2QI-01A-12R-A19W-07
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
- overall_survival_months
- 20
- os_event
- false
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TGF_BETA_SIGNALING+0.430
- WNT_BETA_CATENIN_SIGNALING+0.430
- NOTCH_SIGNALING+0.420
- ANGIOGENESIS+0.340
- APICAL_JUNCTION+0.280
- P53_PATHWAY+0.230
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.220
- UV_RESPONSE_DN+0.220
- HEDGEHOG_SIGNALING+0.200
- MYOGENESIS+0.200
Top 10 suppressed
- E2F_TARGETS-0.640
- G2M_CHECKPOINT-0.560
- MYC_TARGETS_V1-0.520
- MTORC1_SIGNALING-0.430
- MYC_TARGETS_V2-0.340
- ESTROGEN_RESPONSE_LATE-0.330
- UNFOLDED_PROTEIN_RESPONSE-0.300
- CHOLESTEROL_HOMEOSTASIS-0.280
- SPERMATOGENESIS-0.270
- OXIDATIVE_PHOSPHORYLATION-0.260
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-B6-A0IH-01A-11R-A115-07 | — | A | 0.869 |
| 2 | 102d912c-5882-4ae4-9eaf-cbd2f55f66af | — | — | 0.853 |
| 3 | TCGA-BH-A1FH-01A-12R-A13Q-07 | — | A | 0.845 |
| 4 | SRR26320070 | — | — | 0.843 |
| 5 | SRR1516085 | — | — | 0.832 |
| 6 | R163 | — | — | 0.830 |
| 7 | 1ab4a652-7fde-4128-ade4-0a1c56eede64 | — | — | 0.829 |
| 8 | TCGA-AC-A3HN-01A-11R-A213-07 | — | A | 0.829 |
| 9 | 20020074.LumA | — | A | 0.821 |
| 10 | TCGA-B6-A0RP-01A-21R-A084-07 | — | B | 0.813 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TGF_BETA_SIGNALING | 0.430 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.430 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.420 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.340 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.280 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.230 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.220 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.220 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.200 | Inavolisib | — uncovered |
| MYOGENESIS | 0.200 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.180 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.180 | Cobimetinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.160 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.160 | Inavolisib | — uncovered |
| APOPTOSIS | 0.140 | Idelalisib | — uncovered |
| COAGULATION | 0.140 | Binimetinib | — uncovered |
| APICAL_SURFACE | 0.120 | Temsirolimus | — uncovered |
| HEME_METABOLISM | 0.120 | Temsirolimus | — uncovered |
| COMPLEMENT | 0.090 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.080 | Idelalisib | — uncovered |